Clinical Trial Update: Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating tacrolimus and mycophenolate mofetil to prevent acute graft-versus-host disease in patients with advanced hematologic cancers undergo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Leukemia
• Lymphoma
• Multiple Myeloma
• Myelodysplastic Myeloproliferative Diseases
• Myelodysplastic Syndromes
• Myeloproliferative Disorders
• Plasma Cell Neoplasms

Drugs mentioned

• CellCept (Mycophenolate mofetil) (Mycophenolate mofetil)
• Prograf (Tacrolimus) (Tacrolimus)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Chronic Myeloproliferative Disorders, Graft Versus Host Disease | Phase 2 | Status: COMPLETED